SREBF1 and metabolic dysfunction-associated steatotic liver disease: In NAFLD livers, YTHDC2 inhibits the stability of mRNA for SCD1, FASN, SREBP-1c, and ACC1 and blocks their gene expression, resulting in the accumulation of TGs and the progression of MASLD [77].